Reducing inter-individual variability in amikacin clearance in preterm neonates

Paediatric and Perinatal Drug Therapy

Volumn 7, Issue 4, 2006, Pages 163-169

  Allegaert, K ^a   De Hoon, J ^a   Rayyan, M ^a   Van Den Anker, J N ^b,c,d  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Amikacin; Dosing error; Maturation; Neonates; Paediatric vial; Pharmacokinetics; Variability

Indexed keywords

ACETYLSALICYLIC ACID; AMIKACIN; PROSTAGLANDIN SYNTHASE INHIBITOR;

AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG SAFETY; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MAXIMUM ALLOWABLE CONCENTRATION; NEWBORN; PREMATURITY; RESPIRATORY DISTRESS SYNDROME;

EID: 33947316886     PISSN: 14630095     EISSN: None     Source Type: Journal    
DOI: 10.1185/146300906X148558     Document Type: Article

References (25)

1. Kearns GL, Abdel-Rahman SM, Alander SW et al. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349:1157-1167.
2. Van den Anker JN. Pharmacokinetics and renal function in preterm infants. Acta Paediatr 1996;85:1393-1399.
3. Nahata MC. Drug formulations. In: Yaffe SM, Aranda JV eds. Neonatal and pediatric pharmacology. 3th ed. Philadelphia: Lippincott, Williams and Wilkins; 2005
4. Guignard JP. The adverse renal effects of prostaglandin-synthesis inhibitors in the newborn rabbit. Semin Perinatol 2002;26:398-405.
5. Allegaert K, Vanhole C, de Hoon J et al. Non-selective cyclo-oxygenase inhibitors and glomerular filtration rate in preterm neonates. Pediatr Nephrol 2005;20:1557-1561.
6. Van Overmeire B, Allegaert K, Casaer A et al. The prophylactic administration of ibuprofen in premature infants. Lancet 2004;364:1945-1949.
7. Koren G, James A, Perlman M. A simple method for the estimation of glomerular filtration rate by gentamicin pharmacokinetics during routine drug monitoring in the newborn. Clin Pharmacol Ther 1985;38:680-685.
8. Zarowitz BJ, Robert S, Peterson EL. Prediction of GFR using aminoglycoside clearance in critically ill medical patients. Ann Pharmacother 1992;26:1205-1210.
9. Langhendries JP, Battisti O, Bertrand JM et al. Adaptation in neonatology of the once-daily concept of aminoglycoside administration: evaluation of a dosing chart for amikacin in an intensive care unit. Biol Neonate 1998;74:351-362.
10. Mattie H. The importance of pharmacokinetics and pharmacodynamics for effective treatment of infections. Clin Invest 1993;71:480-482.
11. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987,155:93-99.
12. Langhendries JP, Battisti O, Bertrand JM et al. Once-a-day administration of amikacin in neonates: assessment of nephrotoxicity and ototoxicity. Dev Pharmacol Ther 1993;20:220-230.
13. De Hoog M, Mouton JW, Schoemaker RC, Verduin CM, van den Anker JN. Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring. Clin Pharmacol Ther 2002;71:349-358.
14. De Hoog M, Mouton JW, van den Anker JN. New dosing strategies for antibacterial agents in the neonate. Semin Fetal Neonatal Med 2005;10:185-194.
15. Allegaert K, Anderson BJ, Cossey V, Holford NH. Limited predictability of amikacin clearance in extremely preterm neonates at birth. Br J Clin Pharmacol 2006;61:39-48.
16. Allegaert K, Cossey V, Rayyan M, Vanhole C, Devlieger H. Administration of betamethasone before birth has no effect on amikacin pharmacokinetics in preterm infants at birth. Paed Perinat Drug Ther 2005;6:149-153.
17. Allegaert K, Debeer A, Cossey V, Rayyan M, Devlieger H. Dopamine is not an independent risk factor for reduced amikacin clearance in extremely low birth weight infants. Pediatr Crit Care Med 2006;7:143-146.
18. Allegaert K, Anderson B. Antenatal steroids and neonatal renal function. Arch Dis Child 2006;91:451-453.
19. Ferner RE, Langford NJ, Anton C et al. Random and systematic medication errors in routine clinical practice: a multicentre study of infusions, using acetylcysteine as an example. Br J Clin Pharmacol 2001;52:573-577.
20. Reilly KM. Problems in administration techniques and dose measurement that influence accuracy of i.v. drug delivery. Am J Hosp Pharm 1987;44:2545-2550.
21. Allen EM, Van Boerum DH, Olsen AF, Dean JM. Difference between the measured and ordered dose of catecholamine infusions. Ann Pharmacother 1995;29:1095-1100.
22. Philips JB, 3rd, Geerts M, Dew A, Cassady G. The accuracy of amikacin administration in neonates. Pediatr Pharmacol (New York) 1983;3:127-130.
23. Anton C, Ferner RE. Medication errors detected in infusions. Arch Intern Med 2003;163:982
24. Allegaert K, Anderson B, Vrancken M et al. Impact of a paediatric vial on the magnitude of systematic medication errors in neonates. Paed Perinat Drug Ther 2006;7:59-63
25. Van den Anker J. Managing drugs safely. Semin Fetal Neonatal Med 2005;10:73-81.